
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity has positioned itself for sustained growth following the successful rebranding from PerkinElmer, bolstered by a diversified portfolio that includes high-growth software solutions and a robust life sciences reagents franchise. The company's strategic focus on high-margin segments, such as immunodiagnostics and autoimmune testing, alongside continuous margin improvements driven by operational efficiencies, enhances its financial profile and profitability potential. Furthermore, Revvity's competitive advantages in reimbursement and market expansion in key areas such as the US, Europe, and China underpin a favorable outlook for ongoing revenue growth.
Bears say
Revvity's stock outlook is dampened by declining revenue in its key market of China, particularly within the Immunodiagnostics segment, which reported a double-digit percentage decrease in the second quarter of 2025. This decline contributes to broader concerns regarding customer demand due to poor economic conditions and potential industry funding cuts, negatively impacting growth and market share. Additionally, macroeconomic challenges, such as supply chain disruptions and inflationary pressures, pose risks to Revvity's operational performance and product delivery capabilities.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares